Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00193115
Status:
COMPLETED
Last Update Posted:
2010-08-04
First Post:
2005-09-12
Brief Title:
Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Organization Data
Organization:
SCRI Development Innovations LLC
Class:
OTHER
Study ID:
SCRI BRE 69
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
SCRI Development Innovations LLC
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Denise A Yardley MD
Old Organization:
Sarah Cannon Research Institute
Collaborators
| Name | Class |
|---|---|
| Aventis Pharmaceuticals | INDUSTRY |